Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer

Prostate

Volumn 71, Issue 11, 2011, Pages 1178-1188

  Ghadersohi, Ali ^a,c   Sharma, Satish ^a   Zhang, Shaozeng ^a   Azrak, Rami G ^a   Wilding, Gregory E ^a   Manjili, Masoud H ^b   Li, Fengzhi ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Pathology ^*  (United States)

Author keywords

PDEF; prostate cancer; selenium; survivin

Indexed keywords

PROSTATE DERIVED ETS TRANSCRIPTION FACTOR; SURVIVIN; TRANSCRIPTION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; DOWN REGULATION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN EXPRESSION; SURVIVAL RATE; TISSUE MICROARRAY;

CELL LINE, TUMOR; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 79958204970     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21333     Document Type: Article

References (27)

1. Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J, Grall F, Dube A, Weiss A, Brown L, Quinn G, Kas K, Endress G, Kunsch C, Libermann TA,. PDEF, a novel prostate epithelium-specific transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem 2000; 275: 1216-1225. (Pubitemid 30051174)
2. Moussa O, Turner DP, Feldman RJ, Sementchenko VI, McCarragher BD, Desouki MM, Fraig M, Watson DK,. PDEF is a negative regulator of colon cancer cell growth and migration. J Cell Biochem 2009; 108: 1389-1398.
3. Kas K, Finger E, Grall F, Gu X, Akbarali Y, Boltax J, Weiss A, Oettgen P, Kapeller R, Libermann TA,. ESE-3, a novel member of an epithelium-specific ets transcription factor subfamily, demonstrates different target gene specificity from ESE-1. J Biol Chem 2000; 275: 2986-2998. (Pubitemid 30082077)
4. Gu X, Zerbini LF, Otu HH, Bhasin M, Yang Q, Joseph MG, Grall F, Onatunde T, Correa RG, Libermann TA,. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res 2007; 67: 4219-4226. (Pubitemid 46815068)
5. Johnson TR, Koul S, Kumar B, Khandrika L, Venezia S, Maron PD, Meacham RB, Koul HK,. Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: Regulation of MMP 9 by PDEF. Mol Cancer 2010; 9: 148.
6. Ghadersohi A, Dalin P, Fayazi Z, Hicks DG, Winston JS, Li F,. Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibit breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res Treat 2007; 102: 19-130.
7. Turner DP, Moussa O, Sauane M, Fisher PB, Watson DK,. Prostate-derived Ets factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer. Cancer Res 2007; 67: 1618-1625. (Pubitemid 46383387)
8. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK,. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 2003; 63: 4626-4631. (Pubitemid 36951040)
9. Ghadersohi A, Odunsi K, Zhang S, Azrak RG, Bundy BN, Manjili MH, Li F,. Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. Int J Cancer 2008; 123: 1376-1384.
10. Sood AK, Saxena R, Groth J, Desouki MM, Cheewakriangkrai C, Rodabaugh KJ, Kasyapa CS, Geradts J,. Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. Hum Pathol 2007; 1628-1638. (Pubitemid 47589085)
11. Gleason DF, Mellinger GT,. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111: 58-64.
12. Gleason DF,. Histology grading of prostate cancer. A perspective. Human Pathol 1992; 23: 273-279.
13. Ghadersohi A, Sood AK,. Prostate epithelium-derived Ets transcription factor mRNA is over expressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen. Clin Cancer Res 2001; 7: 2731-2738. (Pubitemid 32911378)
14. Zhao H, Whitfield LM, Xu T, Botstein D, Brooks JD,. Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells. Mol Biol Cell 2004; 15: 506-519. (Pubitemid 38146469)
15. Kaplan EL, Meir P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-486.
16. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG,. Design and analysis of randomized clinical trails requiring prolonged observation of each patient. Br J Cancer 1977; 35: 1-39. (Pubitemid 8018922)
17. Tsujimoto Y, Nonomura N, Takayama H, Yomogida K, Nozawa M, Nishimura K, Okayama A, Nozaki M, Aozasa K,. Utility of immunohistochemical detection of prostate-specific Ets for the diagnosis of benign and malignant prostatic epithelial lesions. Int J Urol 2002; 9: 167-172. (Pubitemid 34535474)
18. Nozawa M, Yomogida K, Kanno N, Nonomura N, Miki T, Okuyama A, Nishimune Y, Nozaki M,. Prostate-specific transcription factor hPSE is translated only in normal prostate epithelial cells. Cancer Res 2000; 60: 1348-1352. (Pubitemid 30152005)
19. Clement IP,. Lessons from basic research in selenium and cancer prevention. J Nutr 1998; 128: 1844-1845.
20. Azrak RG, Frank CL, Ling X, Slocum HK, Li F, Foster BA, Rustum YM,. The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells. Mol Cancer Ther 2006; 5: 2540-2548. (Pubitemid 44650918)
21. Witkowski CM, Rabinovitz I, Nagle RB, Affinito KS, Cress AE,. Characterization of integrin subunits, cellular adhesion and tumorgenicity of four human prostate cell lines. J Cancer Res Clin Oncol 1993; 119: 635-696.
22. Li F,. Role of survivin and its splice variants in tumourigenesis. Br J Cancer 2005; 92: 212-216. (Pubitemid 40343130)
23. Li F,. Survivin study: What is the next wave ? J Cell Physiol 2003; 197: 8-29. (Pubitemid 37486223)
24. Mostofi FK, Sesterhenn I, Davis CJ, Sobin LH,. Histological typing of prostate tumors, World Health Organization, International histological classification of tumors. 2nd edition. Berlin: Springer; 2002.
25. Gunawardane RN, Sgroi DC, Wrobel CN, Koh E, Daley GQ, Brugge JS,. Novel role for PDEF in epithelial cell migration and invasion. Cancer Res 2005; 65: 11572-11580. (Pubitemid 41821716)
26. Seth A, Watson DK,. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005; 41: 2462-2478. (Pubitemid 41540623)
27. Azrak RG, Frank CL, Ghadersohi A, Rustum YM,. Silencing survivin results in synergy between methylseleninic acid and paclitaxel against skov3 ovarian cancer cells. Cancer Biol Ther 2008; 7: 1901-1908.